Full text is available at the source.
Abstract
The dual GLP-1R/GIPR agonist BGM0504 is being evaluated for safety and efficacy in adults with overweight or obesity.
- Safety and tolerability of BGM0504 are primary concerns in the evaluation process.
- Pharmacokinetics (PK) will provide information on how the drug is absorbed, distributed, metabolized, and excreted in the body.
- Pharmacodynamics will assess the drug's effects on the body and how it influences weight management.
- Efficacy outcomes will focus on the drug's ability to produce significant weight loss in the target population.
Simplified